Sight Sciences (SGHT) Q1 2026: Glaucoma Revenue Keeps the Lights On, Dry Eye Starts a Quiet Fire, and Guidance Keeps Getting Pulled Up

Nasdaq: SGHT • First Quarter 2026 results

Overview: Revenue, Margin, and a Guide to the Future

Sight Sciences, Inc. (Nasdaq: SGHT) delivered a Q1 2026 report that looks more like a validation of its product mix than a one-night stand with the market. Total revenue came in at $19.7 million, up 13% versus the same period a year ago. The distribution of strength is telling: Interventional Glaucoma contributed $18.3 million, up 7% YoY, while Interventional Dry Eye produced $1.4 million—a remarkable 244% year-over-year jump and an 87% lift from Q4 2025. If you’re wondering about EPS, the press release doesn’t publish a quarterly EPS figure or an explicit earnings surprise; it’s a revenue-and-margins story, not a per-share recital.

The company emphasizes a high-margin core: gross margin stood at 86% for the quarter, essentially flat versus the prior year. In other words, the growth is not coming from margin-destroying gambits but from a healthy top-line expansion that preserves profitability. The message on the cost side matters when you’re juggling a growth-equity thesis with the discipline of a high-mix device business.

Financial Highlights

Total revenue: $19.7 million, up 13% YoY
Interventional Glaucoma revenue: $18.3 million, up 7% YoY
Interventional Dry Eye revenue: $1.4 million, up 244% YoY and up 87% from Q4 2025
Gross margin: 86%, flat year over year
Cash usage: $7.0 million in the quarter
Cash and cash equivalents: $85.0 million as of March 31, 2026
Guidance: Raised full-year 2026 revenue guidance

What It Might Mean for SGHT and the Sector

The quarter adds to the case that Sight Sciences is a glaucoma-centric play with a rising Dry Eye contribution. The 18.3 million from Interventional Glaucoma, while modestly up year over year, remains the backbone of top-line growth. The Dry Eye line—still a small slice—has the look of a growth engine in the making, with a triple-digit YoY pace and a clear, if still early, trajectory toward meaningful scale.

A healthy 86% gross margin is the kind of stat that makes equity analysts comforted by leverage—scale, pricing power, and a favorable mix can turn a fairly straightforward revenue beat into a more durable earnings narrative down the road. The lack of an explicit EPS figure today means investors must be patient for the next 90-120 days to see whether operating expenses compress or stay steady as the top line grows.

The cash runway is another quiet input into the story. With $85 million in cash as of March 31, 2026, the company has a buffer to fund growth initiatives or opportunistic investments without immediate recourse to external financing. The reported burn of $7 million in Q1 is meaningful but manageable in the context of the cash cushion, suggesting the company can pursue growth without sacrificing liquidity.

Industry and Peer Implications

For sector peers, Sight’s mix shift underscores the value of a diversified interventional portfolio within ophthalmology. If Dry Eye momentum sustains, the company could prove that a multi-indication platform value proposition is not just a novelty but a path to more durable revenue streams. Margin stability amid growth is a textbook signal for the benefit of scale and payer negotiation leverage—two levers that often separate the flock from the flock of flops in med-tech equities.

Outlook and What to Watch

Management’s raise of full-year 2026 revenue guidance is the clearest signal of optionality, even if the specific revenue target remains to be disclosed in subsequent communications. In earnings-language terms, this is a green light on the revenue forecast, but investors will still want to see a formal EPS pathway and a crisp EPS consensus from the Street to anchor any stock multiple adjustments.

The next chapters to watch are: (1) whether the Dry Eye growth can sustain a rapid pace in a more challenging reimbursement environment, (2) any scale-up in international markets or new product introductions that could shift the revenue mix, and (3) whether operating expenses begin to meaningfully impact the bottom line as the company invests in growth or international expansion.

Bottom Line

Sight Sciences’ Q1 2026 results paint a picture of a company navigating a growth runway with a healthy cash position and a margin profile that suggests meaningful long-term profitability if the top line can continue to expand. The absence of a concrete EPS figure or earnings surprise leaves the market to infer a trajectory, but the raised revenue guidance implies that management believes the growth narrative still has room to run. For investors scanning the broader ophthalmology and med-tech space, SGHT offers a case study in how a product mix shift—favored by a high-margin, device-led model—can produce top-line resilience even as the company charts its path toward explicit earnings clarity.